SOURCE: Cavit Sciences, Inc.

April 30, 2008 08:00 ET

Cavit Sciences, Inc. Announces Supplement Line Names

MIAMI, FL--(Marketwire - April 30, 2008) - Cavit Sciences, Inc. ("Cavit") (OTCBB: CVIT) announced today the names of its two supplement lines. AMERICARE HEALTH PRODUCTS™ is the first line and MD Solution™ is the second line.

AMERICARE HEALTH PRODUCTS™ -- The supplement products in this line will be marketed and sold initially in Central America, South America and Mexico. The initial three products to be launched were previously announced. Distribution in China and Europe will follow shortly thereafter.

MD Solution™ -- This line is comprised of premium products that enhance certain conditions. The first two products that will be launched in the MD Solution™ line are:

1) Dr. HeartWell™, Cardiovascular Maintenance Formula and

2) Dr. PlumbWell™, Prostate Maintenance Formula

The premium line will be manufactured in the US and marketed to baby boomers that understand the importance of quality supplements in maintaining a healthy lifestyle. Additional products in this line have been formulated and will be added to the line in the near future.

Cavit's products will make people feel better, allowing them to maintain a healthy and quality lifestyle. Our supplement formulas are the result of over 50 years of research conducted by medical doctors, biologists, researchers and scientists. Cavit's trademarked logos, artwork and drawings for AMERICARE HEALTH PRODUCTS™, MD Solution™, Dr. HeartWell™ and Dr. PlumbWell™ will be available on our website shortly.

Cavit Sciences, Inc. ("Cavit") is a biotechnology company that has developed two supplement lines with products that enhance, improve, maintain and support the body by beneficially affecting various conditions and is engaged in developing treatments and prevention for cancer, viral infections, opportunistic infections, related diseases and the immune system. Product information and updates will soon be available on Cavit's website. Additional information regarding our supplement lines, treatment, development and Company information is available on the Company's website at:

Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by Cavit. These factors include, but are not limited to: (i) the ability of Cavit to successfully raise financing, (ii) the ability of Cavit to finalize its manufacturing and distribution facilities, and (iii) the ability of Cavit to successfully commercialize its products in certain markets. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Cavit's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" for Cavit on Form 10K-SB filed on April 18, 2008.

Contact Information